loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Procter & Gamble Health Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Procter & Gamble Health Ltd. 01 Aug 2025 14:54 PM
Result PDF

Q1FY26 Quarterly Result Announced for Procter & Gamble Health Ltd.

Pharmaceuticals company Procter & Gamble Health announced Q1FY26 results

  • Company delivered a strong performance with sales of Rs 333 crore, up 20% versus a year ago.
  • Profit After Tax (PAT) stood at Rs 66 crore, versus Rs 17 crore a year ago.

Milind Thatte, Managing Director, P&G Health India, said: "We are pleased with the continued momentum and strong start to the FY26. These results are a reflection of our commitment towards addressing the evolving needs of our consumers and healthcare professionals, via superior brand building and go to market initiatives while improving supply chain capabilities.

“Our strategy, centered on a focused portfolio of quality, trusted, and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption and an agile accountable organization, is delivering balanced and sustainable growth results. We continue to drive engagement for our consumers and healthcare professionals alike, through innovation backed by science and meaningful interventions to make life a little better every day”.

Result PDF

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q3FY25 results

Q3FY25 Financial Highlights:

  • The third quarter reported sales of Rs 304 crore, up 23% versus the comparable period previous year
  • PAT of Rs 61 crore, up 31% versus comparable period a year ago, owing to superior brand building activities and supported by strengthened supply chain and go-to-market capabilities.
  • The Board of Directors has recommended a final dividend of Rs 45 per Equity Share, for the Financial Year ending March 31, 2025

Commenting on the results, Milind Thatte, Managing Director, P&G Health India, said, “This was a period of purposeful transformation and acceleration. We invested in initiatives to address the changing needs of our consumers and healthcare professionals, while strengthening our go-to-market and supply chain capabilities. Our strategy - centered on a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure, helped us build a strong foundation for long-term growth. This integrated strategy continues to guide our efforts to generate sustainable, balanced top- and bottom-line growth, along with value creation for our consumers, customers, and shareholders alike”

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q2FY25 results

  • The Company reported sales of Rs 304 crore, flat versus a year ago.
  • The Profit After Tax (PAT) for the quarter was Rs 91 crore, up 26% versus a year ago.
  • Profit After Tax (PAT) was up 13% versus a year ago.
  • The Board has declared an interim dividend of Rs 80 per equity share for the FY25. The record date for the dividend will be February 21, 2025.

Milind Thatte, Managing Director, P&G Health India, said: “This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network. We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike.”

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q1FY25 results

  • Reported sales of Rs 310 crore, change 3% compared to Q1FY24.
  • Profit After Tax (PAT) of Rs 82 crore, change 26% compared to Q1FY24.
  • Operational PAT is up by 8% compared to Q1FY24.

Milind Thatte, Managing Director, P&G Health India, said: “Our firstquarter results represent a sequential improvement. Our strategy, centered on a focused portfolio of quality, trusted, and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution, and value), constructive disruption and an agile accountable organization”.

“We are dedicated to enhancing consumer awareness programs and strengthening our relationships with our customers and stakeholdeRs We continue to invest in initiatives that address the evolving needs of both consumers and healthcare professionals, along with strengthening our go-to-market model. We have also strengthened our reach, distribution, and retail execution, positioning us for long-term competitiveness”.

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q3FY24 results:

Financial Highlights:

  • Procter & Gamble Health Limited reported a decrease in sales and profit after tax for the Q3FY24. The total sales for the quarter were Rs 248 crore compared to Rs 316 crore a year ago, marking a downturn. Correspondingly, the Profit After Tax (PAT) also declined by 21% to Rs 46 crore.
  • For the nine-month period ending March 31, 2024, P&G Health's sales were recorded at Rs 852 crore, which exhibited a slight reduction from the previous year's sales of Rs 913 crore.
  • The PAT for the nine-month period stood at 184 crore, experiencing a decrease from the Rs 200 crore reported in the prior year.

Milind Thatte, Managing Director, P&G Health India, said, “The Company’s continued efforts to strengthen our reach and distribution with a transformed go-to-market model reflected in a one-time impact on the quarter’s sales owing to the transition and optimization of trade management and inventory. However, we have seen sales recover in the months of March and April.

We continue to drive operational efficiency and explore innovative solutions to accelerate category growth and demand for our portfolio of trusted, quality healthcare brands. The quarter also witnessed prescription growth and share gain for our doctor detailed products indicating a robust demand, and increased efforts to improve awareness of our self-select products.

We remain confident in our integrated growth strategy of a focused product portfolio where performance drives brand choice, superiority, productivity, constructive disruption, and an agile and accountable organization structure to help drive growth and value creation,”he added.

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q2FY24 results:

  • In a challenging operating environment, the company reported sales of Rs 304 crore, at par vs a year ago.
  • The Profit After Tax (PAT) for the quarter was Rs 72 crore, down 6% vs year ago, owing to one-time items in the quarter.
  • Excluding this one-time impact, Profit After Tax (PAT) was up by 2% vs a year ago.

Milind Thatte, Managing Director, P&G Health India, said, “This has been a challenging quarter for the Company on account of an overall slowdown in the Vitamins, Minerals and Supplements category coupled with a delayed seasonal onset. The team continued to stay resilient. With improved productivity, efficiency and continued strategic investments, we have been able to deliver a modest topline and bottom-line.

We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure. We are confident that this strategy combined with our operational agility will help us navigate the mid-term and deliver balanced growth.”

 

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q4FY23 & FY23 results:

  • Q4FY23:
    • Reported a sale of Rs 306.6 crore up by about 3% versus Q4FY22.
    • The sales grew at low single digit against the headwinds of slowing down of the category in Q4FY23.
    • The company reported a PAT of Rs 29.8 crore, a decline of 28% against Q4FY22 on account of higher material costs and one-time employee costs.
  • FY23:
    • The company has recorded a strong performance with sales of Rs 1,206 crore, up by 10% vs. FY22.
    • Profit after tax (PAT) for FY23 is Rs 229 crore, up by 19% versus FY22.
    • The board of directors has recommended a final dividend of Rs 50 per equity share, for FY23.

“We continued our efforts towards brand and category development and thus delivered a strong performance in the fiscal, marked by consistent growth across all our brands. The quarter, however, witnessed a category slowdown across our portfolio. Despite these challenges, we continued our commitment to our strategy of five integrated choices: a portfolio of daily-use products where performance drives brand choice; superiority across product, package, brand communication, retail execution, and value; productivity; constructive disruption of the entire value chain; and a highly efficient and effective organization structure.

We raised awareness and education among our consumers through initiatives like Neuropathy Awareness Week, wherein leading Global Health Experts converged to address the growing Public Health Concern of Peripheral Neuropathy. This also reinforced our efforts towards building an ecosystem for scientific collaboration and knowledge-sharing among healthcare professionals.

We also commemorated World Health Day by launching the Pragati Utsav, an initiative to raise awareness and empower the healthcare professionals of rural hinterlands, on Vitamin B deficiency. We bolstered our go-to-market strategy and strengthened our partnerships across omni-channel stores, increasing the availability and access of our brands across online and offline platforms, thereby helping meet the needs of our consumers and customers.

We launched the first-of-its-kind policies for employees, including the end-to-end support for children with special needs and a co-pay India Day Care policy, We continued to foster an environment of equal opportunities at the workplace. SEHAT, our flagship CSR program, continued to remain a priority during this fiscal year where we continued to strengthen public health through our strategic initiatives,” said Milind Thatte, Managing Director, Procter & Gamble Health.

 

Result PDF

Pharmaceuticals firm Procter & Gamble Health announced Q3FY23 (quarter ending June) results:

  • Total sales of Rs 316.3 crore for the quarter ended March 31, 2023, vs Rs 262.2 crore, a year ago, up by 21%.
  • Profit After Tax (PAT) was Rs 59.2 crore, up by 16% vs a year ago.
  • Sales for the nine-month period ending March 31, 2023, was Rs 912.8 crore vs Rs 803.2 crore a year ago.
  • PAT for a nine-month period was Rs 199.7 crore vs Rs 151.4 crore a year ago, despite the high inflationary pressures

Mr. Milind Thatte, Managing Director, P&G Health India, said, “We continue to register a consistent growth in this quarter despite a challenging macro-economic environment. This has been made possible through our integrated growth strategies of expanded reach and improved productivity, while we continue to create awareness among our patients and consumers alike. The cornerstone of our approach continues to be our robust product line, which helps meet the rising demand for daily supplements, thereby helping us deliver the 6th consecutive quarter of strong growth. Our focus brands, Evion, Neurobion and Livogen continue to perform exceptionally well. The quarter also saw Neurobion regain its position as India’s No. 1 Nerve Care Brand, while Livogen’s exceptional performance continued behind the award winning campaign ‘Na Na Anemia’ with Diagnostic camps across the country. Under our flagship CSR Program, SEHAT, in partnership with Tata Trust’s ‘Yes! To Poshan’Program, we continued to showcase our commitment towards the cause of maternal & child health.”.

“The quarter also saw us receive various prestigious recognitions. We are thankful to the CSR Summit and Awards 2023, CII, Exchange4media and Obesity International for recognizing our Corporate Social Responsibility and Consumer Awareness efforts. These recognitions have further fueled our passion and commitment to serve Indian consumers and help them live healthier lives,” he concluded.

 

 

 

Result PDF

Procter & Gamble Health announced Q1FY23 results:

  • The company recorded sales of Rs 1,092 crore for the fiscal year ending 30 June 2022, up by 10% vs a year ago
  • Profit After Tax (PAT) for the year ended 30th June 2022 is Rs 193 crores, up by 9%

Mr. Milind Thatte, Managing Director, P&G Health India, said, “We have registered consistent growth in revenue in recent quarters in a challenging environment which saw the industry facing headwinds across many categories. This has been a result of extensive efforts across all fronts to improve awareness and accessibility of our superior, quality products, and better serve our customers, consumers, partners and communities. We continued our efforts to create awareness through integrated campaigns encouraging consumers to identify symptoms and seek timely treatment. Our team stepped up on scientific education efforts for healthcare practitioners through accredited symposiums, roundtables and congresses with leading medical and pharmacy associations. This year, we also launched the ‘P&G Health Academy’, a virtual platform that brings together health experts from across the globe to converge, share and learn. We strengthened our go-to-market strategy through new initiatives that aim to increase reach and distribution. We continued to invest in strengthening public health through our flagship CSR program ‘SEHAT’ (meaning health) with 9 bespoke initiatives, while making strong progress on gender diversity, equality and inclusion through our i-RISE program.”

 

Result PDF

Procter & Gamble Health declares Q4FY22 result:

  • Procter & Gamble Health announces third quarter results showing 14% growth in net profits.
  • Sales of Rs 262 crores and PAT of Rs 51.2 Crores for quarter ended March 31, 2022
  • Sales for the quarter up by 23%
  • The Company has delivered total sales of Rs 262 crores for the quarter ended March 31, 2022 vs Rs 214 crores, up by 23% vs year ago. The Profit After Tax (PAT) was Rs 51.2 crores, up by 224% vs year ago. Increase in PAT is driven by higher sales and lower marketing and depreciation charge vs same period last year.
  • Sales for the nine-month period ending March 31, 2022, were Rs 803 crores, vs Rs 710 crores up 13% vs a year ago. PAT for nine-month period is Rs 151 crore Vs Rs 143 crore a year ago, despite high inflationary pressures.

Mr. Milind Thatte, Managing Director, P&G Health India, said, “We have been able to register consistent growth in revenue and earnings in recent quarters. Our strong portfolio of products that address the increasing demand for daily supplementation and a renewed focus on expanded reach and improved productivity continue to form the pillars of our strategy. We will leverage our strengths in medico-marketing, technology and distribution, in order to better serve the consumers and customers who count on us.”

“We continue our efforts in promoting consumer education, raising awareness around women’s health and overall health and wellness. This year, we launched ‘Women in Healthcare’ summit as a platform to encourage more women to join the healthcare and pharma sectors. We continue to strengthen and expand our projects under SEHAT, our CSR program that aims at contributing to building a healthier India. Recently, we partnered with Apnalaya, to extend our support to the urban poor and provide care to underprivileged pregnant women, new mothers and newborns,” he added.

 

 

Result PDF

Trending News

ACE and Sanghvi Movers have signed a strategic MoU

ACE and Sanghvi Movers have signed a strategic MoU

Published on 12-Dec-2025 09:05

Chalet Hotels has announced its plans to acquire a resort in Udaipur

 Chalet Hotels has announced its plans to acquire a resort in Udaipur

Published on 12-Dec-2025 09:04

Union Cabinet is expected to consider the Insurance Amendment Bill that proposes major regulatory changes

Union Cabinet is expected to consider the Insurance Amendment Bill that proposes major regulatory changes

Published on 12-Dec-2025 09:01

Mexico government has announced raising import tariffs on vehicles, two-wheelers, and auto parts

Mexico government has announced raising import tariffs on vehicles, two-wheelers, and auto parts

Published on 12-Dec-2025 09:00

Cipla launches Yurpeak (tirzepatide) therapy.

Cipla has announced the launch of Yurpeak (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes. 

Published on 11-Dec-2025 09:06

US Fed cuts interest rate range

US Federal Reserve cut interest rate to a range between 3.5% and 3.75%, the lowest level in almost 3-years at its 3rd consecutive meeting but signaled borrowing costs are unlikely to drop further in the near term. 

Published on 11-Dec-2025 09:05

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status